Hedge Funds Gear Up for a Rare IPO

AN2 Therapeutics hopes to buck the recent trend for new issues.

James MacDonald/Bloomberg

James MacDonald/Bloomberg

The first company in some time with significant hedge fund ownership is expected to go public this week.

AN2 Therapeutics said in an updated regulatory filing that it plans to offer four million shares for between $14 and $16 per share. At the midpoint range, that would raise a modest $60 million.


To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.